HER2Bi-armed activated T cells (Barbara Ann Karmanos Cancer Institute)

HER2Bi-armed activated T cells (HER2 BATs) is an autologous cell-based immunotherapy developed by researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University. The production process involves collecting a patient's T cells via leukapheresis, activating them ex vivo with the anti-CD3 monoclonal antibody OKT3, and expanding them in the presence of interleukin-2 (IL-2). These activated T cells (ATC) are then 'armed' with a bispecific antibody (HER2Bi) that targets both CD3 on the T cells and HER2 on the surface of cancer cells. This arming enables the T cells to bypass MHC-restricted recognition, allowing them to directly bind and kill HER2-expressing tumor cells (including those with low HER2 expression, IHC 0-2+) through the release of cytotoxic granules like perforin and granzyme B. The therapy is primarily being evaluated in Phase II clinical trials as a consolidation treatment for triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy, and has also been studied in other HER2-expressing solid tumors including prostate and pancreatic cancers.

Other names

HER2-bispecific antibody-armed activated T cellsHER-2-bispecific antibody-armed activated T cellsHER 2-bispecific antibody-armed activated T cellsanti-CD3 x anti-HER2 armed activated T cellsanti-CD-3 x anti-HER2 armed activated T cellsanti-CD 3 x anti-HER2 armed activated T cellsHER2Bi-armed T cellsHER-2Bi-armed T cellsHER 2Bi-armed T cells